Plandai Biotechnology, Inc. Announces Completion of $13 Million Production Facility
LOGAN, UT – December 22, 2014 – Plandaí Biotechnology, Inc. (OTCQB: PLPL) (“Plandaí” or “the Company”), a developer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today announced completion of the Company’s production facility in South Africa. Further, the Company announced that samples from the first batch of Phytofare® Catechin Complex, which is derived from green tea, are being delivered to testing facilities for final profiling which will take place once vendors return from holiday. ...Read More →
Plandai Biotechnology Receives Approval to Grow Cannabis for Medical Research from Uruguay’s Minister of Public Health
SEATTLE, WA — October 29, 2014 — Plandaí Biotechnology, Inc. (OTCQB: PLPL) (“Plandaí” or “the Company”), a developer of highly bioavailable plant extracts for industries including health, wellness, nutriceutical, and pharmaceutical, today announced that Uruguay’s Ministry of Public Health has approved an academic collaboration between Plandaí and the Group of Medicinal Chemistry from the School of Science at the University of the Republic (“University”) in Montevideo, Uruguay. The approval, issued in September 2014, allows Plandaí to grow cannabis in conjunction with ...Read More →
Plandaí Biotechnology’s Technology Could Prove Potent in Battling Alzheimers Disease
Written by Ι Stock Market Media Group Staff — October 21, 2014
In the recently released preliminary results from Plandaí Biotechnology’s (OTCQB: PLPL) human clinical trial that compared its green tea extract to a commercially available extract, Professor Anne Grobler and her team at North West University in South Africa proved that all 8 catechins found in the green tea plant were absorbed into the bloodstream of those using Phytofare™ Catechin Complex, including, the most potent catechin of the eight, epigallocatechin-3-gallate or EGCG.
Plandaí’s ...Read More →
Plandaí Biotechnology’s Green Tea Extract Delivers Favorable Preliminary Results in Human Clinical Trial
Written by ι Stock Market Media Group Staff — September 10, 2014
Plandaí Biotechnology (OTCQB: PLPL) recently released the preliminary results from its human clinical trial where the company’s green tea extract, Phytofare™ Catechin Complex, was clinically tested and compared to a commercially available green tea extract. In the clinical trial, Plandaí’s Phytofare extract product showed greater bioavailability to participants than did the commercial extract by a factor of 10.
These results echo the USDA’s findings that were published in 2012. The USDA ...Read More →
Marijuana Entrepreneur Jamen Shively Goes Public with Plandai Biotechnology, Inc.
Written by ι Stock Market Media Group — February 14, 2014
If Plandaí Biotechnology (OTCQB: PLPL) investors liked the idea of Diego Pellicer co-founder Jamen Shively working with the company from the outside, then they’ll love the idea that he’s now on the inside of this public biotech. Jamen Shively, a former Microsoft executive turned marijuana entrepreneur, has gone public being named to the Board of Directors at Plandaí.
His experience at Microsoft alone makes this a great business move, but the media’s attraction ...Read More →
Marijuana Entrepreneur Jamen Shively Discusses Plandai Biotechnology, Branding Cannabis, and Legalization
Written by ι Stock Market Media Group Staff — February 4, 2014
Plandaí Biotechnology (OTCQB: PLPL) recently entered into what could very well be the industry’s biggest agreement to date. At the time, many investors may have viewed it as just another licensing agreement, but as Plandaí lays the groundwork for its future, the deal with Diego Pellicer, Inc. and Diego Pellicer Worldwide permits the company to use the Diego Pellicer name for its Phytofare™ cannabis extracts. But, at the same time, it ...Read More →